Sclerotic bone metastases

Last revised by Dr Joachim Feger on 20 Jul 2022

Sclerotic or osteoblastic bone metastases are distant tumor deposits of a primary tumor within bone characterized by new bone deposition or new bone formation.

Bone metastases are the most common malignancy of bone of which sclerotic bone metastases are less common than lytic bone metastases.

The diagnosis is usually established by a combination of imaging and the known presence of a primary tumor that is associated with sclerotic bone metastases. It can also be proven histologically.

Osteoblastic bone metastases are characterized by increased bone formation 2. However, the exact mechanism that leads to osteoblastic formation is not entirely elucidated. It is assumed that several tumor-derived growth factors increase osteoblast activity while osteoclast activity is restricted 3,4.

Sclerotic bone metastases can arise from several different primary malignancies including 1-3:

Sclerotic bone metastases typically present as radiodense bone lesions that are round/nodular with relatively well-defined margins 3. Radiographs are specific but suffer from low sensitivity 1.

CT can detect osteoblastic metastases with a higher sensitivity than plain radiographs and shines in the assessment of bones which are characterized by a small bone marrow cavity and a high amount of cortical bone such as the ribs 2,3.

On CT sclerotic bone metastases typically present as hyperdense lesions, but display a lower density than enostosis 5. A mean CT attenuation threshold of 885 HU and a maximum attenuation threshold of 1060 HU has been found supportive in the differentiation of untreated osteoblastic and enostosis in study 7, but the exclusive use of attenuation values for the assessment of sclerotic bone lesions has been discouraged 8.

MRI features high sensitivity and high specificity for the demonstration of bone metastases in general and for assessing the bone marrow 2,3. It can differentiate predominantly osteoblastic from osteolytic bone metastases 9  as well as easily demonstrate and assess complications such as pathological fractures or spinal cord compression 2,3.

A disadvantage of MRI is that the detection is poor in bones with a small marrow cavity such as the ribs and these bones are better investigated with CT 2,3.

  • T1: low signal intensity
  • T2: low to isointense 2,9 
  • SWI: low signal intensity on the inverted magnitude and phase images 9
  • T1 C+ (Gd): variable

Bone scintigraphy (99mTc MDP) is very sensitive for the detection of osteoblastic providing information on osteoblastic activity but suffers from specificity with a false-positivity rate ranging up to 40% 1.

PET features high sensitivity in the detection of bone metastases especially 18 NaF-PET is suitable for the detection of sclerotic metastases since it shows tracer uptake in locations with osteoblastic activity and is more accurate than FDG-PET 3.

The radiological report should include a description of the following 2:

  • location and size including the whole extent of disease load
  • tumor margins and transition zone
  • aggressive features
    • cortical destruction/breach
    • pathologic fracture
    • soft tissue extension
    • aggressive periosteal reaction
    • pain attributable to the lesion (if known)

Treatment of bone metastases, in general, is usually planned by a multidisciplinary team 10. See article: bone metastases

Osteoblastic metastases have a lower fracture risk than lytic or mixed bone metastases 11-13.

ADVERTISEMENT: Supporters see fewer/no ads

Cases and figures

  • Case 1: from prostate cancer
    Drag here to reorder.
  • Case 2: from breast cancer
    Drag here to reorder.
  • Case 3: from breast cancer
    Drag here to reorder.
  • Case 4: neuroblastoma metastases
    Drag here to reorder.
  • Case 5: from prostate cancer
    Drag here to reorder.
  • Case 7: metastases from prostate carcinoma
    Drag here to reorder.
  • Case 8: metastases from breast carcinoma
    Drag here to reorder.
  • Case 9: from prostate cancer
    Drag here to reorder.
  • Case 10: from prostate cancer
    Drag here to reorder.
  • Case 11: from breast cancer
    Drag here to reorder.
  • Case 12: from prostatic carcinoma
    Drag here to reorder.
  • Case 13: from prostate cancer
    Drag here to reorder.
  • Case 14: from prostate cancer
    Drag here to reorder.
  • Case 15: from prostate cancer
    Drag here to reorder.
  • Case 16: from prostate cancer
    Drag here to reorder.
  • Updating… Please wait.

     Unable to process the form. Check for errors and try again.

     Thank you for updating your details.